For the first time this year, BioWorld’s Biopharmaceutical Index has entered positive territory, now showing a modest rise of 3.2% as the world limps further away from the worst of the COVID-19 pandemic. Despite the Russian invasion of Ukraine, rising inflation, and skyrocketing gas prices, the biopharma industry remains center-stage when it comes to preparing for another unexpected health crisis and for harnessing the knowledge of the last two years to fight stubborn diseases such as cancer and Alzheimer’s disease.
A spring of hope has emerged for BioWorld’s Drug Developers Index (BDDI) with stocks moving in a positive direction in recent weeks, much in line with the broader markets. The BDDI is currently down for the year by 15.5%, but that is an improvement over the 21% decline at the end of February. Likewise, the Nasdaq Biotechnology Index and the Dow Jones Industrial Average are showing similar upward trajectories, but are still down by 11.1% and 4.2%, respectively. It is the first time this year stocks have begun to rise.
The tides have turned for med-tech financings as private companies are now raising the largest proportion of money. In the early months of 2021, 2020 and 2019, public companies took the greatest share. However, amounts raised overall are down by 50% over the same period of 2021 and the number of transactions has fallen 17%.